TRCT
EUCRU

Tower Research Capital (TRC)’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Tower Research Capital (TRC)’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$1K – 6785
2022
Q2 		$1K Buy
+100
New +$993 ﹤0.01% 5955
2021
Q4 		– Sell
-95
Closed -$1K – 6816
2021
Q3 		$1K Hold
95
– – ﹤0.01% 5603
2021
Q2 		$1K Hold
95
– – ﹤0.01% 5316
2021
Q1 		$1K Sell
95
-1
-1% -$11 ﹤0.01% 5254
2020
Q4 		$1K Buy
+96
New +$975 ﹤0.01% 5059

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Tower Research Capital (TRC)'s EUCRU Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q3 2022, closing a stake of 100 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in EUCRU in Q4 2020 and held it in 5 quarters. The position peaked at $1K in Q2 2022. 13 funds tracked by Wall St. Rank hold EUCRU as of Q3 2022.

  • Tower Research Capital (TRC) reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q3 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 100 Eucrates Biomedical Acquisition Corp. Unit shares in Q3 2022, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s Eucrates Biomedical Acquisition Corp. Unit position peaked at $1K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.